Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

NEW YORK, Jan 6 (Reuters) - Medical-device maker Stryker (SYK.N), opens new tab on Monday agreed to acquire Inari Medical (NARI.O), opens new tab, which makes devices that treat patients with ...

Inari Medical Background Information (This description ... for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism ...

Inari Medical, which has a market value approaching $3 billion, is expected to enhance Stryker's portfolio by expanding its treatment options for venous thromboembolism, a condition characterized ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

Inari shareholders are getting a fair price ... with a primary focus on stroke and aneurysm treatment including coils, catheters, microcatheters, stents, and mechanical thrombectomy devices.

Highlights,Stryker agrees to acquire Inari Medical for $80 per share, totaling $4.9 billion,Acquisition strengthens Stryker’s position in the venous thromboembolism (VTE) treatment market,Expected to ...